Crizotinib resistance: implications for therapeutic strategies

Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, 350, 2129, 10.1056/NEJMoa040938 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Soda, 2007, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature, 448, 561, 10.1038/nature05945 Rikova, 2007, Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer, Cell, 13, 1190, 10.1016/j.cell.2007.11.025 Takeuchi, 2008, Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts, Clin Cancer Res, 14, 6618, 10.1158/1078-0432.CCR-08-1018 Shaw, 2009, Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J Clin Oncol, 27, 4247, 10.1200/JCO.2009.22.6993 Gainor, 2013, ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer, Clin Cancer Res, 19, 4273, 10.1158/1078-0432.CCR-13-0318 Ou, 2012, Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology, Oncologist, 17, 1351, 10.1634/theoncologist.2012-0311 Kwak, 2010, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, N Engl J Med, 363, 1693, 10.1056/NEJMoa1006448 Camidge, 2012, Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study, Lancet Oncol, 13, 1011, 10.1016/S1470-2045(12)70344-3 Malik, 2014, U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive, Clin Cancer Res, 20, 2029, 10.1158/1078-0432.CCR-13-3077 Shaw, 2013, Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, 368, 2385, 10.1056/NEJMoa1214886 Solomon, 2014, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, 371, 2167, 10.1056/NEJMoa1408440 Doebele, 2012, Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer, Cancer, 118, 4502, 10.1002/cncr.27409 Rangachari, 2015, Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers, Lung Cancer, 88, 108, 10.1016/j.lungcan.2015.01.020 Solomon, 2016, Intracranial efficacy of crizotinib versus chemotherapy in patients with advanced ALK-positive non-small-cell lung cancer: results from PROFILE 1014, J Clin Oncol, 10.1200/JCO.2015.63.5888 Chun, 2012, Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?, Cancer Biol Ther, 13, 1376, 10.4161/cbt.22255 Gainor, 2013, The central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancer, J Thorac Oncol, 8, 1570, 10.1097/JTO.0000000000000029 Costa, 2015, Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases, J Clin Oncol, 33, 1881, 10.1200/JCO.2014.59.0539 Costa, 2011, CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib, J Clin Oncol, 29, e443, 10.1200/JCO.2010.34.1313 Tang, 2014, Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar, Int J Cancer, 134, 1484, 10.1002/ijc.28475 Takeda, 2013, Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement, J Thorac Oncol, 8, 654, 10.1097/JTO.0b013e31828c28e7 Weickhardt, 2012, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, 7, 1807, 10.1097/JTO.0b013e3182745948 Gan, 2014, Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib, Int J Radiat Oncol Biol Phys, 88, 892, 10.1016/j.ijrobp.2013.11.010 Choi, 2010, EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors, N Engl J Med, 363, 1734, 10.1056/NEJMoa1007478 Doebele, 2012, Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer, Clin Cancer Res, 18, 1472, 10.1158/1078-0432.CCR-11-2906 Toyokawa, 2014, Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib, J Thorac Oncol, 9, e86, 10.1097/JTO.0000000000000358 Sasaki, 2011, A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors, Cancer Res, 71, 6051, 10.1158/0008-5472.CAN-11-1340 Katayama, 2012, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers, Sci Transl Med, 4, 120ra17, 10.1126/scitranslmed.3003316 Bresler, 2014, ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma, Cancer Cell, 26, 682, 10.1016/j.ccell.2014.09.019 Katayama, 2011, Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK, Proc Natl Acad Sci USA, 108, 7535, 10.1073/pnas.1019559108 Tanizaki, 2012, Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer, Clin Cancer Res, 18, 6219, 10.1158/1078-0432.CCR-12-0392 Kimura, 2015, Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with EML4-ALK fusion gene, J Thorac Oncol, 10, 527, 10.1097/JTO.0000000000000381 Lovly, 2014, Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer, Nat Med, 20, 1027, 10.1038/nm.3667 Wilson, 2015, A functional landscape of resistance to ALK inhibition in lung cancer, Cancer Cell, 27, 397, 10.1016/j.ccell.2015.02.005 Crystal, 2014, Patient-derived models of acquired resistance can identify effective drug combinations for cancer, Science, 346, 1480, 10.1126/science.1254721 Hrustanovic, 2015, RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer, Nat Med, 21, 1038, 10.1038/nm.3930 Marsilje, 2013, J Med Chem, 56, 5675, 10.1021/jm400402q Yamada, 2012, Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells, Clin Cancer Res, 18, 3592, 10.1158/1078-0432.CCR-11-2972 Kim, 2013, A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype, PLoS One, 8, e76999, 10.1371/journal.pone.0076999 Kobayashi, 2013, Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies, J Thorac Oncol, 8, e75, 10.1097/JTO.0b013e318293d96f Kim, 2013, Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation, Mol Oncol, 7, 1093, 10.1016/j.molonc.2013.08.001 Kogita, 2014, Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition, Int J Oncol, 45, 1430, 10.3892/ijo.2014.2574 Kim, 2016, Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial, Lancet Oncol, 17, 452, 10.1016/S1470-2045(15)00614-2 Crino, 2016, Ceritinib in patients with ALK-rearranged non-small cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2, J Clin Oncol, 10.1200/JCO.2015.65.5936 Ou, 2015, Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study, J Clin Oncol, 34, 661, 10.1200/JCO.2015.63.9443 Shaw, 2016, Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial, Lancet Oncol, 17, 234, 10.1016/S1470-2045(15)00488-X Gettinger, 2015, Brigatinib (AP26113) Efficacy and safety in ALK+ NSCLC: phase 1/2 trial results, J Thorac Oncol, 10, S66 Shaw, 2014, Ceritinib in ALK-rearranged non-small-cell lung cancer, N Engl J Med, 370, 1189, 10.1056/NEJMoa1311107 Friboulet, 2014, The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer, Cancer Discov, 4, 662, 10.1158/2159-8290.CD-13-0846 Katayama, 2014, Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib, Clin Cancer Res, 20, 5686, 10.1158/1078-0432.CCR-14-1511 Ou, 2015, I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib, Lung Cancer, 88, 231, 10.1016/j.lungcan.2015.02.005 Fontana, 2015, Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK, Cancer Med, 4, 953, 10.1002/cam4.413 Ou, 2014, Next-generation sequencing reveals a novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib, J Thorac Oncol, 9, 549, 10.1097/JTO.0000000000000094 Zou, 2015, PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models, Cancer Cell, 28, 70, 10.1016/j.ccell.2015.05.010 Shaw, 2016, Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F, N Engl J Med, 374, 54, 10.1056/NEJMoa1508887 Gadgeel, 2015, Pooled analysis of CNS responses to alectinib in two studies of pre-treated ALK+ NSCLC, J Thorac Oncol, 10, S66 Johnson, 2014, J Med Chem, 57, 4720, 10.1021/jm500261q Kogita, 2015, Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer, Int J Oncol, 46, 1025, 10.3892/ijo.2014.2797 Tanimoto, 2014, Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells, Oncotarget, 5, 4920, 10.18632/oncotarget.2055 Chen, 2014, Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance, Clin Cancer Res, 20, 1204, 10.1158/1078-0432.CCR-13-1733 Sang, 2013, Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer, Cancer Discov, 3, 430, 10.1158/2159-8290.CD-12-0440 Socinski, 2013, A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer, Clin Cancer Res, 19, 3068, 10.1158/1078-0432.CCR-12-3381 Gainor, 2015, A phase II trial of AUY922, a heat shock protein 90 (HSP90) inhibitor, in ALK-positive lung cancer patients previously treated with ALK inhibitors, J Thorac Oncol, 10, S66 Ota, 2015, Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer, Clin Cancer Res, 21, 4014, 10.1158/1078-0432.CCR-15-0016 Gainor JF, Shaw AT, Sequist LV et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer (NSCLC): a retrospective analysis. Clin Cancer Res 2016. In press. Garon, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, N Engl J Med, 372, 2018, 10.1056/NEJMoa1501824 Gainor, 2015, Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib, Clin Cancer Res, 21, 2745, 10.1158/1078-0432.CCR-14-3009